Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up

To the Editor: Boer and Jemec first described the use of topical 15% resorcinol for hidradenitis suppurativa (HS) in a small retrospective study in 2010,1 reporting a marked decrease in pain and mean duration of the lesions. In this study we assessed the effects of resorcinol in a prospective open trial in HS by using both clinical measures and ultrasonography. Ultrasound examination in HS provides anatomic information that is clinically unavailable and may be helpful for follow-up.2,3 We recruited participants with Hurley stage I and II HS.